Concepedia

Publication | Open Access

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction

DOIFull Paper Access

36

Citations

16

References

2017

Year

Zanfina Ademi, Alena M. Pfeil, Elizabeth Hancock, David Trueman, R Haroun, C. Deschaseaux, Matthias Schwenkglenks
Swiss Medical Weekly

Abstract

The treatment of HFrEF patients with sacubitril/valsartan versus enalapril is cost effective, if a willingness-to-pay threshold of CHF 50 000 per QALY gained ratio is assumed.

References

YearCitations

Page 1